2020 Drug Pricing Packaging 
Pharmaceutical Technology
NOVEMBER 21, 2022
According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.
Pharmaceutical Technology
JUNE 9, 2025
The European average time between market authorisation and patient access between 2020 and 2024 was defined according to the time (in days) between approval and pricing as well as the time (in days) between approval and reimbursement. The worsening access conditions for originator medicines in the EU are highlighted in the graph below.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 7, 2025
The Importance of Generic Drugs in Healthcare Generic drugs offer several benefits to patients and the healthcare system: Cost-effectiveness: Generic drugs are typically much cheaper than brand-name medications, making treatment more accessible to patients. ” WHO.int, 2020. ” JAMA, 2016. Shrank, W.H.,
Safe Biologics
DECEMBER 6, 2023
REMINDER: FDA Draft Guidance Would Remove Interchangeability Statement from Interchangeable Biosimilars Comments Due November 17th On September 15th, the Food and Drug Administration (FDA) released draft guidance removing the interchangeability statement from the product label/package insert. ASBM surveys of U.S. However, S.6
Pharmaceutical Technology
NOVEMBER 21, 2022
According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. It is too early to say because we have not seen the whole package of measures yet.
Proxsys Rx
OCTOBER 6, 2022
That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package.
Expert insights. Personalized for you.
69 
Let's personalize your content